Merck’s Keytruda receives four approvals in Japan, including in high-risk early-stage TNBC

Combination treatment may dramatically improve survival in brain cancer

A study suggests that laser interstitial thermal therapy using NeuroBlate may enhance the effectiveness of the immunotherapy drug pembrolizumab (Keytruda) for patients with recurrent high grade astrocytoma, including glioblastoma.

March 06, 2026

Vol.52 No.09

Drugs & Targets

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) reduced the risk of event-free survival events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.

March 06, 2026

Vol.52 No.09

Clinical Roundup

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment, according to a Mayo Clinic-led study.

February 27, 2026

Vol.52 No.08

In Brief

WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy

A WVU Cancer Institute team has achieved a global medical first in a clinical trial examining the efficacy of subcutaneous blinatumomab (Blincyto) in treating one of the rarest and most aggressive forms of leukemia.

February 20, 2026

Vol.52 No.07

Clinical Roundup

Neoadjuvant pembrolizumab helps shrink tumors in patients with desmoplastic melanoma

In a recent multi-institutional clinical trial, 71% of patients who received the immunotherapy drug pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, before surgery had no detectable cancer remaining at the time of surgery.

February 06, 2026

Vol.52 No.05

Merck’s Keytruda receives four approvals in Japan, including in high-risk early-stage TNBC

YOU MAY BE INTERESTED IN

Combination treatment may dramatically improve survival in brain cancer

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy

Neoadjuvant pembrolizumab helps shrink tumors in patients with desmoplastic melanoma

Renew today!

Subscriber content

Never miss an issue!

Login